Aimee L. Jackson
Research Subjects
Research Interests
Aimee L. Jackson has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Peter S. Linsley
Department of Biology, Rosetta Inpharmatics, Seattle, WA, USA
11 shared publicationsJulja Burchard
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
8 shared publicationsJanell Schelter
Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
5 shared publicationsJie Guo
Department of Biology, Rosetta Inpharmatics LLC, Seattle, WA, USA
4 shared publicationsLawrence A. Loeb
Departments of Pathology and Biochemistry, The Joseph Gottstein Memorial Cancer Research Laboratory, University of Washington Seattle, Washington, 98195
4 shared publicationsLee Lim
Rosetta Inpharmatics LLC, Seattle, Washington 98109
4 shared publications
Latest Publications
- 1 May 2019
- Published by Oxford University Press (OUP)
- p. A7408
Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis
- 1 May 2019
- Published by Oxford University Press (OUP)
- p. A7408
Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis
- Top Cited Papers
- 20 August 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (3) , 428-444
Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma
Summary: miR‐155, a microRNA associated with poor prognosis in lymphoma and leukaemia, has been implicated in the progression of mycosis fungoides (MF), the most common form of cutaneous T‐cell lymphoma (CTCL). In this study, we developed and tested cobomarsen (MRG‐106), a locked nucleic acid‐modified oligonucleotide inhibitor of miR‐155. In MF and human lymphotropic virus type 1 (HTLV‐1+) CTCL cell lines in vitro, inhibition of miR‐155 with cobomarsen de‐repressed direct miR‐155 targets, decreased expression of multiple gene pathways associated with cell survival, reduced survival signalling, decreased cell proliferation and activated apoptosis. We identified a set of genes that are significantly regulated by cobomarsen, including direct and downstream targets of miR‐155. Using clinical biopsies from MF patients, we demonstrated that expression of these pharmacodynamic biomarkers is dysregulated in MF and associated with miR‐155 expression level and MF lesion severity. Further, we demonstrated that miR‐155 simultaneously regulates multiple parallel survival pathways (including JAK/STAT, MAPK/ERK and PI3K/AKT) previously associated with the pathogenesis of MF, and that these survival pathways are inhibited by cobomarsen in vitro. A first‐in‐human phase 1 clinical trial of cobomarsen in patients with CTCL is currently underway, in which the panel of proposed biomarkers will be leveraged to assess pharmacodynamic response to cobomarsen therapy.
- 20 August 2018
- Published by Wiley in British Journal of Haematology
- Vol. 183 (3) , 428-444
Top Cited PapersCobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma
Summary: miR‐155, a microRNA associated with poor prognosis in lymphoma and leukaemia, has been implicated in the progression of mycosis fungoides (MF), the most common form of cutaneous T‐cell lymphoma (CTCL). In this study, we developed and tested cobomarsen (MRG‐106), a locked nucleic acid‐modified oligonucleotide inhibitor of miR‐155. In MF and human lymphotropic virus type 1 (HTLV‐1+) CTCL cell lines in vitro, inhibition of miR‐155 with cobomarsen de‐repressed direct miR‐155 targets, decreased expression of multiple gene pathways associated with cell survival, reduced survival signalling, decreased cell proliferation and activated apoptosis. We identified a set of genes that are significantly regulated by cobomarsen, including direct and downstream targets of miR‐155. Using clinical biopsies from MF patients, we demonstrated that expression of these pharmacodynamic biomarkers is dysregulated in MF and associated with miR‐155 expression level and MF lesion severity. Further, we demonstrated that miR‐155 simultaneously regulates multiple parallel survival pathways (including JAK/STAT, MAPK/ERK and PI3K/AKT) previously associated with the pathogenesis of MF, and that these survival pathways are inhibited by cobomarsen in vitro. A first‐in‐human phase 1 clinical trial of cobomarsen in patients with CTCL is currently underway, in which the panel of proposed biomarkers will be leveraged to assess pharmacodynamic response to cobomarsen therapy.
- 1 October 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (10) , B4
LB948 Pharmacodynamic activity of a microRNA-29b mimic (MRG-201) in human skin incisions
- 1 October 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (10) , B4
LB948 Pharmacodynamic activity of a microRNA-29b mimic (MRG-201) in human skin incisions
- Open Access
- 7 June 2017
- Published by Wiley in Hematological Oncology
- Vol. 35 (S2) , 275-276
PH 1 TRIAL EVALUATING MRG‐106, A MICRORNA‐155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T‐CELL LYMPHOMA (CTCL) PATIENTS
- 7 June 2017
- Published by Wiley in Hematological Oncology
- Vol. 35 (S2) , 275-276
Open AccessPH 1 TRIAL EVALUATING MRG‐106, A MICRORNA‐155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T‐CELL LYMPHOMA (CTCL) PATIENTS
- Open Access
- 1 March 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (3) , 694-704
The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent
- 1 March 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (3) , 694-704
Open AccessThe Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent
- Open Access
- 1 July 2013
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 66 (2) , 167-176
Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: A scientific review
- 1 July 2013
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 66 (2) , 167-176
Open AccessSafety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: A scientific review
- 1 April 2013
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 12 (2) , 88-98
Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Chronic respiratory diseases are a significant health problem requiring novel approaches to both complement existing therapies and provide breakthrough medicines. Recent clinical advances in understanding the behavior of inhaled oligonucleotides provide the impetus for application of this technology to microRNA therapeutics. MicroRNAs are evolutionarily conserved small regulatory RNA molecules involved in tuning gene networks controlling biological and pathological processes. Deletion or overexpression of microRNAs results in phenotypic changes in animal models of disease such as cancer, fibrosis, diabetes, and inflammation. Inhibition of microRNAs in preclinical models of asthma, cystic fibrosis, and idiopathic pulmonary fibrosis has shown therapeutic promise. In animals, inhibitors of microRNAs directly delivered to the airway at doses suitable for nebulizers or hand-held inhalers up-regulate expression of cohorts of genes containing complementary “seed” sequences for specific and directed microRNA binding within their mRNA untranslated regions. These observations suggest the opportunity to exploit intervention in microRNA biology to create new therapies for chronic pulmonary disorders.
- 1 April 2013
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 12 (2) , 88-98
Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Chronic respiratory diseases are a significant health problem requiring novel approaches to both complement existing therapies and provide breakthrough medicines. Recent clinical advances in understanding the behavior of inhaled oligonucleotides provide the impetus for application of this technology to microRNA therapeutics. MicroRNAs are evolutionarily conserved small regulatory RNA molecules involved in tuning gene networks controlling biological and pathological processes. Deletion or overexpression of microRNAs results in phenotypic changes in animal models of disease such as cancer, fibrosis, diabetes, and inflammation. Inhibition of microRNAs in preclinical models of asthma, cystic fibrosis, and idiopathic pulmonary fibrosis has shown therapeutic promise. In animals, inhibitors of microRNAs directly delivered to the airway at doses suitable for nebulizers or hand-held inhalers up-regulate expression of cohorts of genes containing complementary “seed” sequences for specific and directed microRNA binding within their mRNA untranslated regions. These observations suggest the opportunity to exploit intervention in microRNA biology to create new therapies for chronic pulmonary disorders.
- Open Access
- 1 December 2012
- Published by Elsevier in SLAS Discovery
- Vol. 17 (10) , 1316-1328
A Multiplexed siRNA Screening Strategy to Identify Genes in the PARP Pathway
- 1 December 2012
- Published by Elsevier in SLAS Discovery
- Vol. 17 (10) , 1316-1328
Open AccessA Multiplexed siRNA Screening Strategy to Identify Genes in the PARP Pathway
- Open Access
- 12 October 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 92
Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene
Background: Oxidative Stress contributes to the pathogenesis of many diseases. The NRF2/KEAP1 axis is a key transcriptional regulator of the anti-oxidant response in cells.Nrf2knockout mice have implicated this pathway in regulating inflammatory airway diseases such as asthma and COPD. To better understand the role the NRF2 pathway has on respiratory disease we have taken a novel approach to define NRF2 dependent gene expression in a relevant lung system.Methods: Normal human lung fibroblasts were transfected with siRNA specific for NRF2 or KEAP1. Gene expression changes were measured at 30 and 48 hours using a custom Affymetrix Gene array. Changes in Eotaxin-1 gene expression and protein secretion were further measured under various inflammatory conditions with siRNAs and pharmacological tools.Results: An anti-correlated gene set (inversely regulated byNRF2andKEAP1RNAi) that reflects specific NRF2 regulated genes was identified. Gene annotations show that NRF2-mediated oxidative stress response is the most significantly regulated pathway, followed by heme metabolism, metabolism of xenobiotics by Cytochrome P450 and O-glycan biosynthesis. Unexpectedly the key eosinophil chemokine Eotaxin-1/CCL11 was found to be up-regulated when NRF2 was inhibited and down-regulated when KEAP1 was inhibited. This transcriptional regulation leads to modulation of Eotaxin-1 secretion from human lung fibroblasts under basal and inflammatory conditions, and is specific to Eotaxin-1 asNRF2orKEAP1knockdown had no effect on the secretion of a set of other chemokines and cytokines. Furthermore, the known NRF2 small molecule activators CDDO and Sulphoraphane can also dose dependently inhibit Eotaxin-1 release from human lung fibroblasts.Conclusions: These data uncover a previously unknown role for NRF2 in regulating Eotaxin-1 expression and further the mechanistic understanding of this pathway in modulating inflammatory lung disease.
- 12 October 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 92
Open AccessGene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene
Background: Oxidative Stress contributes to the pathogenesis of many diseases. The NRF2/KEAP1 axis is a key transcriptional regulator of the anti-oxidant response in cells.Nrf2knockout mice have implicated this pathway in regulating inflammatory airway diseases such as asthma and COPD. To better understand the role the NRF2 pathway has on respiratory disease we have taken a novel approach to define NRF2 dependent gene expression in a relevant lung system.Methods: Normal human lung fibroblasts were transfected with siRNA specific for NRF2 or KEAP1. Gene expression changes were measured at 30 and 48 hours using a custom Affymetrix Gene array. Changes in Eotaxin-1 gene expression and protein secretion were further measured under various inflammatory conditions with siRNAs and pharmacological tools.Results: An anti-correlated gene set (inversely regulated byNRF2andKEAP1RNAi) that reflects specific NRF2 regulated genes was identified. Gene annotations show that NRF2-mediated oxidative stress response is the most significantly regulated pathway, followed by heme metabolism, metabolism of xenobiotics by Cytochrome P450 and O-glycan biosynthesis. Unexpectedly the key eosinophil chemokine Eotaxin-1/CCL11 was found to be up-regulated when NRF2 was inhibited and down-regulated when KEAP1 was inhibited. This transcriptional regulation leads to modulation of Eotaxin-1 secretion from human lung fibroblasts under basal and inflammatory conditions, and is specific to Eotaxin-1 asNRF2orKEAP1knockdown had no effect on the secretion of a set of other chemokines and cytokines. Furthermore, the known NRF2 small molecule activators CDDO and Sulphoraphane can also dose dependently inhibit Eotaxin-1 release from human lung fibroblasts.Conclusions: These data uncover a previously unknown role for NRF2 in regulating Eotaxin-1 expression and further the mechanistic understanding of this pathway in modulating inflammatory lung disease.
- 1 August 2012
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 22 (4) , 213-225
Developing microRNA Therapeutics: Approaching the Unique Complexities
MicroRNAs are endogenous small non-coding RNAs that regulate gene expression by interfering with translation or stability of target transcripts. The importance of microRNAs for maintaining biological functions is illustrated by the fact that microRNAs are exploited in nature to regulate phenotypes, and by the diverse disease phenotypes that result when microRNAs are mutated or improperly expressed. Disease-associated microRNAs might therefore represent a new class of therapeutic targets. With the recent demonstration that inhibition of miR-122 reduces viral load in hepatitis C patients, microRNA modulators are no longer merely theoretical, but rather, have become strong candidate therapeutics. The complexity of microRNA biology offers a novel mechanism of action for therapeutic intervention but also poses unique challenges for the development of therapeutic modulators as drugs.
- 1 August 2012
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 22 (4) , 213-225
Developing microRNA Therapeutics: Approaching the Unique Complexities
MicroRNAs are endogenous small non-coding RNAs that regulate gene expression by interfering with translation or stability of target transcripts. The importance of microRNAs for maintaining biological functions is illustrated by the fact that microRNAs are exploited in nature to regulate phenotypes, and by the diverse disease phenotypes that result when microRNAs are mutated or improperly expressed. Disease-associated microRNAs might therefore represent a new class of therapeutic targets. With the recent demonstration that inhibition of miR-122 reduces viral load in hepatitis C patients, microRNA modulators are no longer merely theoretical, but rather, have become strong candidate therapeutics. The complexity of microRNA biology offers a novel mechanism of action for therapeutic intervention but also poses unique challenges for the development of therapeutic modulators as drugs.